We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Seegene

Seegene, Inc. is a developer of multiplex molecular technologies and multiplex clinical molecular diagnostics for inf... read more Featured Products: More products

Download Mobile App





Seegene Receives CE-IVD Mark for Use of Combo Swab with Four COVID-19 Diagnostic Tests

By LabMedica International staff writers
Posted on 02 Sep 2021
Print article
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)
Image: Allplex SARS-CoV-2/FluA/FluB/RSV Assay (Photo courtesy of Seegene, Inc.)
Seegene, Inc. (Seoul, Korea) has obtained CE marking for the use of Combo Swab, a self-collection device with four diagnostic assays.

Combo Swab is a user-friendly swab designed for efficient specimen collection at scale in which patients can easily collect specimen from their nasal and oral cavity under the supervision of a healthcare professional. With the CE-IVD mark, the Combo Swab can be now used with Seegene's four COVID-19 diagnostic assays, including Allplex SARS-CoV-2 Assay, Allplex SARS-CoV-2 Master Assay, Allplex SARS-CoV-2 Variants I Assay, and Allplex SARS-CoV-2/FluA/FluB/RSV Assay. The availability of Combo Swab with the company's diagnostic assays is expected to dramatically improve testing efficiency by facilitating continued testing for a large group of people in much reduced time.

The Combo Swab offers multiple benefits while reducing various inconveniences that nasopharyngeal swabs have. In comparison to the nasopharyngeal swab that needs to insert deeply patient's nasopharynx until resistance is encountered, individuals can collect their own specimen by simply swabbing their mouth and nose without causing any discomfort. Due to its simplicity, it does not require healthcare professionals to take care of each patient, which in turn, allows efficient testing for a large group of people. While Combo Swabs can drastically improve the testing environment for mass testing, it also reduces the risk of accidental exposure to the virus for clinicians as they can maintain distance during the testing procedure.

Seegene said this new testing option will not only expand access to COVID-19 testing, but also minimize the workload for healthcare workers, resolving clinician shortage issues in many countries around the world. Clinical data shows Combo Swabs have accuracy of over 96%, the same accuracy as the results from nasopharyngeal swabs. Countries like the US, UK, and Singapore have already adopted self-collecting devices such as oral and nasal swabs to scale up testing. Most self-administered testing, however, obtains samples from one's mouth or nose, while Seegene's Combo Swab collects specimens from both mouth and nose, therefore, the results obtained using Combo Swabs show higher accuracy over other self-collecting devices.

"With the rapid spread of the Delta variant, surveillance testing is the key to curb the further spread of COVID-19. Under such circumstances, Combo Swabs will facilitate efficient mass testing with its high accuracy," said Min-Cheol Lee, Seegene's Chief Technology Officer. "Seegene owns unique multiplex technologies which obtained over fifty original patents of detecting multiple virus genes in a single test. The combination of Combo Swabs and Seegene's high multiplex technologies will certainly be the optimized solution to scale up the COVID-19 testing and be an essential tool for societies to reopen."

Related Links:
Seegene, Inc.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 RT-PCR Assay
Reliance SARS-CoV-2 RT-PCR Assay Kit

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.